Long-Term Survival, Toxicity Profile, and role of F-18 FDG PET/CT scan in Patients with Progressive Neuroendocrine Tumors Following Peptide Receptor Radionuclide Therapy with High Activity In-111 Pentetreotide
Open Access
- 1 January 2012
- journal article
- Published by Ivyspring International Publisher in Theranostics
- Vol. 2 (5), 472-480
- https://doi.org/10.7150/thno.3739
Abstract
Aim: To study the long term benefits, toxicity and survival rate in patients with neuroendocrine tumors receiving multiple cycles of high activity In-111 Pentetreotide therapy. Moreover, our secondary aim was to evaluate the value of F-18 FDG PET-CT scan as prognostic indicator in this group of patients.Keywords
This publication has 28 references indexed in Scilit:
- Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions.2010
- One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United StatesJournal of Clinical Oncology, 2008
- In BriefCurrent Problems in Surgery, 2006
- Incidence of Small Bowel Cancer in the United States and Worldwide: Geographic, Temporal, and Racial DifferencesCancer Causes & Control, 2005
- Epidemiology of Neuroendocrine TumoursNeuroendocrinology, 2004
- Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors.2003
- Personal dosimetry of the staff during treatment of neuroendocrine tumours with a high dose of Indium-111 Octreotide.2002
- Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findingsSeminars in Nuclear Medicine, 2002
- Somatostatin Receptor: Scintigraphy and Radionuclide TherapyDigestion, 1996
- Radiotherapy with a Radiolabeled Somatostatin Analogue, [111In‐DTPA‐d‐Phe1]‐OctreotideAnnals of the New York Academy of Sciences, 1994